Trial Profile
Safety and Pharmacokinetics study of LY2503029 in patients with advanced solid tumours
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 Dec 2015
Price :
$35
*
At a glance
- Drugs LY 2503029 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 30 Dec 2015 New trial record